Yongin Approves General Industrial Complex Project at Mokshin-ri, Wonsam-myeon, 34,128㎡

Yongin Special City (Mayor Lee Sang-il) announced on the 2nd that it has approved the 'Yongin HL Genomics General Industrial Complex,' a 34,128㎡ project in Mokshin-ri, Wonsam-myeon, Cheoein-gu.

The company plans to begin construction at the end of this year and complete the complex by December 2029. Out of the total area of 34,128㎡, 26,147㎡ (76.6%) is planned as industrial facility land for factories and research facilities.

Regarding this, Mayor Lee Sang-il stated, "Since this is an industrial complex where advanced bio companies with actual demand will be located, we will actively support the seamless development of the facilities."

HL Genomics Co., Ltd. plans to invest a total of 27.5 billion won to develop the site as a medical manufacturing facility industrial complex to expand production capacity for active pharmaceutical ingredients needed for Hallim Pharmaceutical's drug manufacturing.

HL Genomics Co., Ltd. is a subsidiary of Hallim Pharmaceutical, a local company of Yongin. Hallim Pharmaceutical, having received approval from the U.S. Food and Drug Administration (FDA) for current Good Manufacturing Practice (cGMP), began construction of an urban advanced industrial complex in Yurim-dong in June of this year to upgrade production processes for export specialty pharmaceuticals.

As the project operator, HL Genomics Co., Ltd. plans to establish production facilities that meet international standards necessary for biopharmaceutical R&D; and overseas market expansion following the approval of the industrial complex.